Castle Biosciences Inc (NASDAQ:CSTL)
| Market Cap | $1.01B-14.6% |
| Revenue (ttm) | $377.13M+9.8% |
| Net Income | -$23.01M-88.1% |
| EPS | -$0.77-72.1% |
| Shares Out | 30.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 309,216 |
| Open | $33.02 |
| Previous Close | $33.41 |
| Day's Range | $32.54 - $33.37 |
| 52-Week Range | $17.72 - $44.28 |
| Beta | 0.95 |
| Analysts | Buy |
| Price Target | $38.75(+17.92%) |
| Earnings Date | Feb 25, 2027 |
About CSTL
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating CSTL in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 25, 2027Earnings report
$CSTL stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of CSTL by members of U.S. Congress
| Josh GottheimerHouse / D | Sale$1.00K – $15.00K | Mar 15, 2022 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Dec 23, 2020 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Dec 23, 2020 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Dec 22, 2020 |
| Josh GottheimerHouse / D | Purchase$1.00K – $15.00K | Dec 21, 2020 |
Recently reported changes in CSTL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CSTL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CSTL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CSTL Revenue by Segment
| Non-Dermatologic | $55.01M | 53.47% |
| Dermatologic | $47.88M | 46.53% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CSTL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CSTL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CSTL
| IWMiShares Russell 2000 ETF | $26.32M |
| VTIVanguard Morningstar Total Stock Market ETF | $25.38M |
| VXFVanguard Extended Market ETF | $12.92M |
| IWNiShares Russell 2000 Value ETF | $9.46M |
| FESMFidelity Enhanced Small Cap ETF | $7.92M |
| IBBiShares Biotechnology ETF | $7.81M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CSTL’s recent data — informational, not investment advice
What’s Behind the Score
News check: Raised 2026 guidance and revenue growth drive bullish sentiment; positive clinical data and analyst optimism support upside potential.
Recent Insider Activity
Insider Score Trend Over Time
-35.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| XHS | State Street SPDR S&P Health Care Services ETF | 1.26% |
| GNMX | Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF | 0.81% |
| NSCS | Nuveen Small Cap Select | 0.73% |
| SVAL | iShares US Small Cap Value Factor ETF | 0.54% |
| HAPS | Harbor Human Capital Factor US Small Cap ETF | 0.54% |
| LITL | Simplify Piper Sandler US Small-Cap PLUS Income ETF | 0.48% |
| ETHO | Amplify Etho Climate Leadership U.S. ETF | 0.41% |
| FSEV | Fidelity Enhanced Small Cap Value ETF | 0.26% |
| IWC | iShares Micro-Cap ETF | 0.25% |
| ISMD | Inspire Small/Mid Cap ETF | 0.19% |
| BSVO | EA Bridgeway Omni Small-Cap Value ETF | 0.18% |
| IHF | iShares U.S. Healthcare Providers ETF | 0.13% |
Weight is the stock’s share of each fund’s holdings.
